

Summary of Results from Cited Published Literature

Cited published literature may discuss device uses that have not been approved or cleared by FDA.

Data from supporting literature

Literature Reference	Population Studied	Number and Type of Specimens	Device Used	Observed D7S486/CEP 7 Results
Vance et al ¹	AML ^a	179 bone marrow and 47 peripheral blood specimens ^b	Vysis LSI D7S486/CEP 7 probes	Overall 1R2G signal pattern was detected in 4/179 bone marrow specimens and 3/47 peripheral blood specimens. Overall 1R1G signal pattern was detected in 5/179 bone marrow specimens and 1/47 peripheral blood specimens.
Cherry et al ²	MDS ^a	48 bone marrow specimens	Vysis LSI D7S486/CEP 7 probes	Overall 1R2G signal pattern was detected in 3/48 bone marrow specimens. Overall 1R1G signal pattern was detected in 2/48 bone marrow specimens.
Tefferi et al ³	MMM ^a	42 bone marrow and peripheral blood specimens	Vysis LSI D7S486/CEP 7 probes	Overall 1R2G signal pattern was detected in 2/42 bone marrow specimens and 1/42 peripheral blood specimens.

^a AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; MMM: myelofibrosis with myeloid metaplasia

^b Based on unpublished data.

BIBLIOGRAPHY

- Vance GH, Kim H, Hicks GA, et al. Utility of Interphase FISH to Stratify Patients into Cytogenetic Risk Categories at Diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) Clinical Trial (E1900). *Leuk Res.* 2007;31:605-09.
- Cherry A, Brockman S, Paternoster S, et al. Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. *Leuk Res.* 2003;27:1085-1090.
- Tefferi A, Meyer R, Wyatt W, et al. Comparison of peripheral blood interphase cytogenetics with bone marrow karyotype analysis in myelofibrosis with myeloid metaplasia. *Br J Haematol.* 2001;115:316-319.
- Genome Bioinformatics Group of UC Santa Cruz. The UCSC Genome Browser. ©The Regents of the University of California. Available at: <http://genome.ucsc.edu/cgi-bin/hgGateway?hgsid=185806115&clade=mammal&org=Human&db=hg18>. Accessed [April 30, 2013].
- Wiktor AE, Van Dyke DL, Stupca PJ, et al. Preclinical validation of fluorescence in situ hybridization assays for clinical practice. *Genet Med.* 2006;8:16-23.
- US Department of Health and Human Services. *Biosafety in Microbiological and Biomedical Laboratories*, Fifth Edition. Washington, DC: US Government Printing Office; December 2009.
- US Department of Labor, Occupational Safety and Health Administration. 29 CFR Part 1910.1030. *Bloodborne Pathogens*.
- Clinical and Laboratory Standards Institute. *Protection of Laboratory Workers from Occupationally Acquired Infections: Approved Guideline—Third Edition*. CLSI Document M29-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2005.
- World Health Organization. *Laboratory Biosafety Manual*. 3rd ed. Geneva, Switzerland: World Health Organization; 2004.
- Barch MJ, Knutsen T, Spurbeck J, eds. *The AGT Cytogenetics Laboratory Manual*. 3rd ed. Philadelphia, PA: Lippincott-Raven; 1997.
- AMERICAN COLLEGE OF MEDICAL GENETICS (ACMG), Standards and Guidelines for Clinical Genetics Laboratories, 2008 Edition.

TECHNICAL ASSISTANCE

For technical assistance, call Abbott Molecular Technical Services at 1-800-553-7042 (within the US) or +1-630-512-580 (outside the US), or visit the Abbott Molecular website at <http://www.abbottmolecular.com>.

Abbott Molecular Inc. is the legal manufacturer of the Vysis D7S486/CEP 7 FISH Probe Kit.

Patents: abbott.us/patents

VYSIS, LSI, CEP and WCP are trademarks of the Abbott Group of Companies in various jurisdictions. All other trademarks are the property of their respective owners.



Abbott Molecular Inc.
1300 East Touhy Avenue
Des Plaines, IL 60018 USA



Abbott GmbH & Co. KG
Max-Planck-Ring 2
65205 Wiesbaden, Germany

© 2013 Abbott Laboratories
www.abbottmolecular.com
October 2013
30-608510/R1